How GLP-1 Access Actually Works in India

India's GLP-1 market runs on a fact that does not apply anywhere else in this series: Novo Nordisk's Indian patent on semaglutide, the molecule in Ozempic and Wegovy, expired on 20 March 2026. Patent terms are national, not global, and India's expired years before the equivalent US and EU patents. Within a day, at least six Indian drugmakers had launched Central Drugs Standard Control Organisation (CDSCO)-approved generic semaglutide at a fraction of the originator's price. Tirzepatide, the molecule in Mounjaro, is a different story: it remains patent-protected in India, and is sold only by Eli Lilly itself and one Lilly-licensed partner brand. The result is a market split in two, cash-only for almost everyone, and increasingly the focus of drug-safety warnings from India's own regulator about unsupervised use.

Which of the nine brands are CDSCO-approved and sold in India

Five of the nine US brand names correspond to CDSCO-approved, marketed products in India, though not always under the same name or the same commercial structure. Ozempic (semaglutide, Novo Nordisk) launched in India in mid-December 2025 for type 2 diabetes, reportedly priced around Rs 2,200 a week for the starting dose. Wegovy (semaglutide, Novo Nordisk) is also marketed in India for weight management; Novo Nordisk additionally partnered with Mumbai-based Emcure Pharmaceuticals, whose semaglutide brand Poviztra received a CDSCO nod extending its approved use to MASH (metabolic dysfunction-associated steatohepatitis, a liver disease). Rybelsus, oral semaglutide, is sold in India as the reference brand that Indian generic oral semaglutide tablets are now priced against. Mounjaro (tirzepatide, Eli Lilly) launched for type 2 diabetes and obesity and, within roughly a year, became one of the best-selling single brands in the entire Indian pharmaceutical market by value. Trulicity (dulaglutide, Eli Lilly) and Saxenda and Victoza (both liraglutide, Novo Nordisk) are older entrants that have been sold in India for years; by April 2026 they held a combined single-digit percentage share of the GLP-1 category by value, dwarfed by semaglutide and tirzepatide.

Zepbound, the US brand name for tirzepatide as a dedicated weight-management product, does not exist as a separate product in India. Eli Lilly markets the same molecule under the single name Mounjaro for both type 2 diabetes and weight management, and this page found no CDSCO record or company announcement of a Zepbound-branded launch. Foundayo (orforglipron), Eli Lilly's newest, oral, non-peptide entrant, authorised in the UK and US earlier in 2026, likewise turned up no evidence of a CDSCO filing or Indian launch as of this writing; if that changes, it will need a separate check rather than an assumption either way.

The semaglutide patent expiry: the reason this page exists

Patent protection is granted and expires country by country, not globally, because each country's patent office examines and grants its own patent under its own law and timeline. Novo Nordisk's semaglutide patent in India expired on 20 March 2026, roughly a decade ahead of the equivalent expiries expected in the United States and European Union. That gap, not any difference in the drug itself, is why India became the cheapest legitimate market for semaglutide in the world within a day of expiry.

According to reporting based on Drugs Controller General of India (DCGI) approvals and company statements, at least six Indian pharmaceutical companies, Dr Reddy's Laboratories, Sun Pharma, Glenmark Pharmaceuticals, Alkem Laboratories, Zydus Lifesciences and Natco Pharma, launched CDSCO-approved generic semaglutide products on 21 March 2026, the day after patent expiry, with a seventh company, Eris Lifesciences, launching a co-marketed brand the same day through a partnership with Natco. Torrent Pharmaceuticals and Lupin entered shortly after through licensing partnerships with Zydus. By April 2026, according to PHARMATRAC data compiled by the healthcare analytics platform Pharmarack, roughly 25 generic semaglutide brands were competing in the Indian market, with Torrent holding the largest single share of generic semaglutide sales at 38 percent.

Generic semaglutide brand names and prices

On launch day, Novo Nordisk's own semaglutide brands were priced at approximately Rs 8,800 a month for Ozempic and Rs 10,850 a month for Wegovy at their starting doses, according to reporting citing company pricing. The Indian generics that launched against them, on the same day, carried the following brand names and prices, as reported at launch in March 2026:

Dr Reddy's Laboratories launched Obeda, a pre-filled pen for type 2 diabetes, priced at Rs 4,200 a month for the 2 mg and 4 mg doses; the company said it was separately seeking approval for a weight-management indication. Sun Pharma launched two brands: Noveltreat for weight management, in five dose strengths from Rs 3,600 to Rs 8,000 a month, and Sematrinity for type 2 diabetes, from roughly Rs 3,000 to Rs 5,200 a month (quoted at launch as Rs 750 to Rs 1,300 a week). Glenmark launched Glipiq, a vial-and-syringe version priced from Rs 1,300 to Rs 1,760 a month, the cheapest option at launch, alongside a pre-filled pen version whose price the company had not disclosed. Alkem Laboratories launched three brands, Semasize, Obesema and Hepaglide, with a disposable pen at Rs 1,800 a month. Zydus Lifesciences launched three brands, Semaglyn, Mashema and Altreme, at an average of about Rs 2,200 a month, and separately signed licensing partnerships with Lupin and Torrent Pharma to co-market the molecule. Natco Pharma launched Semanat and Semafull, starting at Rs 1,290 a month in vial form, with a pen device planned for April 2026 at Rs 4,000 to 4,500. Eris Lifesciences launched a co-branded product called Sundae, priced to match Natco's starting price.

These figures describe launch pricing in March 2026 and are company-quoted list prices for starting doses, not a live price list; a reader checking current cost should treat them as an order of magnitude (roughly Rs 1,300 to Rs 4,200 a month at launch for generic injectable semaglutide, against Rs 8,800 to Rs 10,850 a month for the originator brands) rather than a quote to act on.

Tirzepatide: still one company, one licensed partner, no generic

Mounjaro (tirzepatide) has been the standout performer in India's GLP-1 category by value. Industry data reported in mid-2026 put tirzepatide at roughly 63 percent of total Indian GLP-1 category sales by moving annual value, against about 30 percent for semaglutide (across both originator and generic brands) and single-digit shares for older molecules dulaglutide and liraglutide. Mounjaro held the top position among all pharmaceutical brands in India, by value, in April 2026, even as generic semaglutide brands multiplied around it.

Because tirzepatide's Indian patent has not expired, this growth has not produced generic competition the way semaglutide's did. Instead, Eli Lilly licensed a second brand, Yurpeak, to Cipla in 2026, aimed specifically at smaller towns where Cipla's distribution network reaches further than Lilly's own. Yurpeak is reported to be priced at parity with Mounjaro, not at a discount: it is a distribution strategy, not a low-cost alternative. A reader looking for a cheaper tirzepatide option in India, generic or otherwise, will not find a CDSCO-approved one on the market as of this writing.

Who pays, and why insurance is mostly not part of the answer

India's health insurance market, regulated by the Insurance Regulatory and Development Authority of India (IRDAI), is structured overwhelmingly around hospitalisation and inpatient indemnity cover. Outpatient costs, including self-administered, ongoing chronic-disease medication of the kind GLP-1 drugs require, are the part of Indian health insurance policies that patients routinely have to pay for themselves, and weight-management use in particular tends to be treated as elective or cosmetic rather than as a covered medical necessity. This page found no IRDAI circular, insurer product filing or regulator statement specifically addressing GLP-1 drug coverage, so it cannot point to a rule that excludes these drugs by name; what can be said, based on the general structure of Indian health insurance and consistent with how outpatient pharmacy costs are treated across the market, is that a patient prescribed semaglutide or tirzepatide in India should expect to pay for it out of pocket, whether the brand is a Rs 1,300-a-month generic or a Rs 10,850-a-month originator.

This is also consistent with why the generic price war landed as significant industry news rather than a routine drug launch: for a market where the buyer is almost always paying cash, a starting price of roughly Rs 1,300 a month versus Rs 8,800 to Rs 10,850 a month is the difference between a treatment that is realistically accessible to a much wider set of patients and one that is not. Novo Nordisk India's own managing director was quoted in March 2026 estimating that of roughly 250 million Indians living with obesity, only around 200,000 were then on any GLP-1 medication, and pointed to awareness, access to specialist care and the need for sustained long-term treatment as barriers at least as significant as price.

Prescription enforcement: CDSCO has already acted, more than once

GLP-1 drugs are prescription-only in India under the Drugs and Cosmetics Rules. Rather than describing this as a formality, it is worth describing what CDSCO has actually done about violations. In March 2026, CDSCO issued an advisory directing manufacturers to stop misleading advertisements or promotional material that could encourage GLP-1 use without medical supervision. By May 2026, the regulator's head, Drugs Controller General of India Rajeev Singh Raghuvanshi, wrote to State Licensing Authorities describing a coordinated, nationwide enforcement drive, stating that CDSCO had inspected online pharmacy warehouses, wholesalers, retail chemists and wellness clinics, and had already issued notices to entities found violating rules on manufacture, sale and promotion of these drugs. The regulator specifically flagged online pharmacies, wellness clinics and slimming centres as channels where GLP-1 drugs were reaching patients without adequate medical supervision, and warned that diversion into unauthorised channels or promotion encouraging irrational, off-label cosmetic use would draw regulatory action.

The government's stated concern is not hypothetical: it lists nausea, vomiting and dehydration as common effects, and pancreatitis, bowel obstruction and kidney injury as more serious ones that make medical supervision, rather than an online purchase with no prescribing physician involved, the relevant safety boundary. This page describes that enforcement position without suggesting how to work around it: a CDSCO-flagged unauthorised channel is a risk this page is written to help a reader avoid, not to route around.

The evidence, one row per claim

Questions people ask

Sources

1. ThePrint, "Rs 325-4,200/month: Dr Reddy's, Sun Pharma, Glenmark kick off generic semaglutide price war", 21 March 2026
2. The South First, "Mounjaro remains number one in India as Torrent captures 38% of the generic semaglutide market", 11 May 2026, citing PHARMATRAC/Pharmarack data
3. ETPharma (The Economic Times), "Cipla to market Lilly's weight-loss drug Tirzepatide under second brand name in India"
4. The Federal, "Ozempic launched in India, priced at Rs 2,200 per week", 12 December 2025
5. Outlook India, "CDSCO Raises Red Flag Over Unauthorised Sale Of Anti-Obesity Drugs", 20 May 2026, quoting DCGI Rajeev Singh Raghuvanshi
6. Inferred from IRDAI's general regulatory structure for health insurance products; no GLP-1-specific coverage rule or exclusion was located